Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 57

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 57
---
, Mr. Marrazzo agreed to provide certain professional services to the Company separate from and in addition to his service as a Board member, and we agreed to pay Mr. Marrazzo an annual fee of $50,000 per year in addition to the grant of an option to purchase 250,000 shares of the Company’s common stock.

The Marrazzo Agreement expired in February 2025. From January 1, 2023 through the termination date, we paid Mr. Marrazzo $50,000 and granted Mr. Marrazzo 250,000 stock options under the Marrazzo Agreement.

Settlement Agreement with Myeloid Therapeutics, Inc.

In December 2021, we entered into a research collaboration and exclusive option agreement (the “Myeloid Collaboration Agreement”) with Myeloid Therapeutics, Inc. (“Myeloid”), during which time we and Myeloid had one common board member, who is also an affiliate of Newpath Partners, L.P., a beneficial owner of more than 5% of our voting securities, and holds more than 30% of Myeloid’s voting securities. In 2023, we terminated the Myeloid Collaboration Agreement.

In January 2024, we entered into a settlement agreement (the “Settlement Agreement”) with Myeloid resolving two arbitration proceedings. Under the terms of the Settlement Agreement, the parties agreed to resolve and settle all disputes between the parties and release all claims between them relating to the Myeloid Collaboration Agreement and the arbitrations in exchange for our payment to Myeloid of $13.5 million, certain mutual covenants, and other consideration. Accordingly, for the year ended December 31, 2023, we recorded a charge of $13.5 million, and paid the $13.5 million during the year ended December 31, 2024.

#### Indemnification Agreements
We have entered into agreements to indemnify our directors and executive officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or

<div align='center'>36</div>

in our right, on account of any services undertaken by such person on behalf of our company or that person’s status as a member of our Board or our executive officer to the maximum extent allowed under Delaware law.

Policies for Approval of Related Party Transactions